Foundery Immune Studio, LLC acquires rights to TREM1, TREM2, and MARCO immune tuning clinical-stage therapies
Acquiring Company
Foundery Innovations, Inc.
Acquired Company
Ikena Oncology
San FranciscoBostonBiotechnologyBiotechnologyHealth CareMedicalTherapeuticsDescription
San Francisco-based Foundery Immune Studio, LLC has acquired worldwide rights for three clinical-stage immune tuning therapies from Ikena Oncology, Inc. These monoclonal antibodies target myeloid cells and are engineered to recalibrate the immune environment within tumors with greater precision, potentially revolutionizing the treatment of cancers, autoimmune conditions, and inflammatory diseases.
Quick answer
Foundery Innovations, Inc. is acquiring Ikena Oncology, announced January 8, 2025. Foundery Innovations, Inc. is based in San Francisco, California, United States.
- How much did Foundery Innovations, Inc. pay for Ikena Oncology?
- The deal value was not disclosed.
- What does Foundery Innovations, Inc. do?
- Foundery Innovations, Inc. is a San Francisco-based Immunotherapy Venture Studio; a novel scientist-driven enterprise accelerating early-stage R&D.
- Where are Foundery Innovations, Inc. and Ikena Oncology based?
- Foundery Innovations, Inc. is based in San Francisco, California, United States. Ikena Oncology is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Foundery Innovations, Inc?
- Fundz holds 1 contact at Foundery Innovations, Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- BioNTech completes acquisition of Biotheus to strengthen oncology strategy (February 4, 2025)
- Flourish Research acquires Diablo Clinical Research to expand therapeutic coverage (February 18, 2025)
- Exicure, Inc. completes acquisition of GPCR Therapeutics USA Inc. to enhance its pipeline for cell and gene therapies (January 22, 2025)
- Vivo Infusion completes acquisition of Neurology Institute of San Antonio and Vista Infusions to expand infusion services (January 9, 2025)
- Novartis to acquire Anthos Therapeutics for up to $3.1 Billion, $3.1B (February 11, 2025)
- Pan-Am Dental completes strategic acquisitions of JB Dental Lab and Avaneer Dental Studio, solidifying its position as a top 10 dental lab group (February 10, 2025)
Who to call at Foundery Innovations, Inc., and when
When Foundery Innovations, Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Foundery Innovations, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Foundery Innovations, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Foundery Innovations, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Foundery Innovations, Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Ikena Oncology?
Ikena Oncology was acquired by Foundery Innovations, Inc., based in San Francisco. The deal was reported on January 8, 2025. Foundery Innovations, Inc. is a San Francisco-based Immunotherapy Venture Studio; a novel scientist-driven enterprise accelerating early-stage R&D. Foundery Innovations, Inc. is privately held and operates in Biotechnology.
When did Foundery Innovations, Inc. acquire Ikena Oncology?
Foundery Innovations, Inc.'s acquisition of Ikena Oncology was reported on January 8, 2025. San Francisco-based Foundery Immune Studio, LLC has acquired worldwide rights for three clinical-stage immune tuning therapies from Ikena Oncology, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Ikena Oncology do?
Ikena OncologyTM is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. It is privately held, operating in Biotechnology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.